Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology test… Read more
Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) - Net Assets
Latest net assets as of September 2025: $38.23 Billion USD
Based on the latest financial reports, Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) has net assets worth $38.23 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($90.98 Billion) and total liabilities ($52.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.23 Billion |
| % of Total Assets | 42.02% |
| Annual Growth Rate | 19.6% |
| 5-Year Change | 153.08% |
| 10-Year Change | N/A |
| Growth Volatility | 13.03 |
Shin Nippon Biomedical Laboratories, Ltd. - Net Assets Trend (2020–2025)
This chart illustrates how Shin Nippon Biomedical Laboratories, Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shin Nippon Biomedical Laboratories, Ltd. (2020–2025)
The table below shows the annual net assets of Shin Nippon Biomedical Laboratories, Ltd. from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $40.09 Billion | +17.34% |
| 2024-03-31 | $34.16 Billion | +29.60% |
| 2023-03-31 | $26.36 Billion | +33.65% |
| 2022-03-31 | $19.72 Billion | +24.52% |
| 2021-03-31 | $15.84 Billion | -3.32% |
| 2020-03-31 | $16.38 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shin Nippon Biomedical Laboratories, Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2257663900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $20.09 Billion | 50.19% |
| Other Components | $19.94 Billion | 49.81% |
| Total Equity | $40.02 Billion | 100.00% |
Shin Nippon Biomedical Laboratories, Ltd. Competitors by Market Cap
The table below lists competitors of Shin Nippon Biomedical Laboratories, Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HBL Corporation
KQ:452190
|
$38.83 Million |
|
Neogrid Participações S.A
SA:NGRD3
|
$38.85 Million |
|
Unibios Holdings S.A
AT:BIOSK
|
$38.86 Million |
|
Forge Resources Corp.
OTCQB:FRGGF
|
$38.87 Million |
|
KAISA GROUP HLDGS
F:KG5
|
$38.82 Million |
|
Lumbee Guaranty Bank
OTCQX:LUMB
|
$38.80 Million |
|
Man Zai Industrial Co Ltd
TWO:4543
|
$38.80 Million |
|
Pappajack Bhd
KLSE:0242
|
$38.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shin Nippon Biomedical Laboratories, Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 34,114,417,000 to 40,022,734,000, a change of 5,908,317,000 (17.3%).
- Net income of 4,924,848,000 contributed positively to equity growth.
- Dividend payments of 2,100,072,000 reduced retained earnings.
- Share repurchases of 325,000 reduced equity.
- Other factors increased equity by 3,083,866,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.92 Billion | +12.31% |
| Dividends Paid | $2.10 Billion | -5.25% |
| Share Repurchases | $325.00K | -0.0% |
| Other Changes | $3.08 Billion | +7.71% |
| Total Change | $- | 17.32% |
Book Value vs Market Value Analysis
This analysis compares Shin Nippon Biomedical Laboratories, Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | $391.24 | $9.51 | x |
| 2021-03-31 | $377.94 | $9.51 | x |
| 2022-03-31 | $469.86 | $9.51 | x |
| 2023-03-31 | $629.61 | $9.51 | x |
| 2024-03-31 | $819.43 | $9.51 | x |
| 2025-03-31 | $961.35 | $9.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shin Nippon Biomedical Laboratories, Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.31%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.19%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 2.31x
- Recent ROE (12.31%) is below the historical average (21.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 15.66% | 17.52% | 0.37x | 2.39x | $921.57 Million |
| 2021 | 23.27% | 24.23% | 0.41x | 2.35x | $2.09 Billion |
| 2022 | 36.44% | 40.16% | 0.45x | 2.01x | $5.17 Billion |
| 2023 | 23.12% | 24.15% | 0.44x | 2.18x | $3.44 Billion |
| 2024 | 16.21% | 20.91% | 0.35x | 2.24x | $2.12 Billion |
| 2025 | 12.31% | 15.19% | 0.35x | 2.31x | $922.57 Million |
Industry Comparison
This section compares Shin Nippon Biomedical Laboratories, Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) | $38.23 Billion | 15.66% | 1.38x | $38.82 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |